Akari Therapeutics, Plc (AKTX)
Develops experimental cancer-fighting antibodies that deliver toxic payloads to tumor cells
$8.43-0.00%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-79.1%
The outlook
AKTX is trading near its 52-week lows with both its 50- and 200-day moving averages well above the current price. The two analysts covering the stock hold a Strong Buy consensus, with an average price target implying substantial upside from here. Overall sentiment remains neutral, reflecting the stock's depressed technical position against analyst optimism.
What’s behind the score
Analyst consensusStrong Buy — 1.5 avg of 2 analysts
Price trendBelow its 50- & 200-day averages
52-week range12% of the way from its 52-week low to high
Price targetAvg target +237% vs current price
Analyst price target
~12-month · 2 analysts$28.39average target+236.8% vs now
Now $8.43
Low $26.78High $30.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$14.8M
52-wk high
$49.60
52-wk low
$3.02
50-day avg
$11.79
200-day avg
$13.01
Trailing P/E
—